IPP Bureau
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
By IPP Bureau - August 04, 2022
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Zydus receives final approval from the USFDA for Ivermectin Cream
By IPP Bureau - August 04, 2022
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Merck KGaA posts higher earnings, profits across business segments
By IPP Bureau - August 04, 2022
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
By IPP Bureau - August 04, 2022
The WAVEsystem with the WAVEcontrol 4.0 embedded
Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr
By IPP Bureau - August 04, 2022
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Sandu Pharmaceuticals launches Sandu Kumarvin
By IPP Bureau - August 04, 2022
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
By IPP Bureau - August 04, 2022
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
By IPP Bureau - August 04, 2022
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
By IPP Bureau - August 03, 2022
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr
By IPP Bureau - August 03, 2022
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
By IPP Bureau - August 03, 2022
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
PIB: Quality control of Ayush drugs
By IPP Bureau - August 03, 2022
PIB: Budget allocation and utilization of funds under National Ayush Mission
By IPP Bureau - August 03, 2022
The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.
PIB: Development of Ayush entrepreneurship
By IPP Bureau - August 03, 2022
Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.
Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal
By IPP Bureau - August 03, 2022
Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country
